Old Web
English
Sign In
Acemap
>
Paper
>
MA02.06 Phase 1b Study of Pelcitoclax (APG-1252) in Combination With Osimertinib in Patients With EGFR TKI-Resistant NSCLC
MA02.06 Phase 1b Study of Pelcitoclax (APG-1252) in Combination With Osimertinib in Patients With EGFR TKI-Resistant NSCLC
2021
L. Zhang
H. Zhao
Y Ma
Ying Cheng
Yufen Zhao
Jiuwei Cui
C. Yang
Jun-Wu Zhang
Peng Wang
Li Xu
Jinpu Yu
L. Men
E. Liang
D. Yang
Y. Zhai
Keywords:
egfr tki
Osimertinib
Oncology
Medicine
in patient
Internal medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]